Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023 – Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and...

ESMO Congress 2023 – Presentation

ESMO Congress 2023 – Presentation Luveltamab Tazevibulin (STRO-002), an Anti-Folate Receptor Alpha Antibody Drug Conjugate, Demonstrates Clinical Activity in Recurrent Epithelial Endometrial Cancer: STRO-002-GM1 Phase 1 Dose Expansion...
Sutro Biopharma, Inc.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.